The impact of BRAF mutation on survival of patients with metastatic colorectal cancer depending on the type of surgical and systemic treatment
Introduction . Metastatic colorectal cancer (mCRC) remains a leading cause of cancer-related mortality worldwide. BRAF mutations (predominantly V600E) occur in 5–10% of mCRC cases and are associated with an aggressive disease phenotype, poor response to conventional chemotherapy, and dismal prognosis. In the Russian...